Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848046 | 0.87 | PPARG (0.49) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1849198 | 0.87 | PPARG (0.49) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1851202 | 0.84 | PPARG (0.44) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL2180568 | 0.84 | PPARG (0.70) | PPARGRARGRXRAPPARA | |
| SCHEMBL2180994 | 0.82 | PPARG (0.57) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1845921 | 0.82 | PPARG (0.41) | PPARGRARGRXRAPPARA | |
| SCHEMBL1847231 | 0.81 | PPARG (0.53) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL2179642 | 0.81 | PPARG (0.72) | PPARGRARGRXRAPPARAALOX15 | |
| SCHEMBL9325005 | 0.79 | PPARG (0.48) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1848107 | 0.79 | PPARG (0.47) | PPARGRARGRXRAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210095345-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2021-04-01 | — | — | US | disclosed |
| US-20150073025-A1 | METHOD FOR IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8846315-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110166185-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166185-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885RARG 2343/4885RXRA 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.